Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties

[1]  A. Lykkesfeldt,et al.  Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling , 2013, Breast Cancer Research and Treatment.

[2]  P. Roca,et al.  Mitochondrial dynamics is affected by 17β-estradiol in the MCF-7 breast cancer cell line. Effects on fusion and fission related genes. , 2012, The international journal of biochemistry & cell biology.

[3]  M. Esteller,et al.  DNA methylation profiling in the clinic: applications and challenges , 2012, Nature Reviews Genetics.

[4]  Mark A. LaBarge.  On stem cells in the human breast. , 2012, Cold Spring Harbor perspectives in biology.

[5]  A. Pandiella,et al.  Sox2 expression in breast tumours and activation in breast cancer stem cells , 2012, Oncogene.

[6]  T. Reichert,et al.  The human HECA interacts with cyclins and CDKs to antagonize Wnt-mediated proliferation and chemoresistance of head and neck cancer cells. , 2012, Experimental cell research.

[7]  Michael Jones,et al.  Genome-wide association analysis identifies three new breast cancer susceptibility loci , 2012, Nature Genetics.

[8]  T. Hickey,et al.  FOXA1: master of steroid receptor function in cancer , 2011, The EMBO journal.

[9]  Wing-Kin Sung,et al.  Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state , 2011, Molecular systems biology.

[10]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[11]  Yaojiong Wu,et al.  Epigenetic Dysregulation in Mesenchymal Stem Cell Aging and Spontaneous Differentiation , 2011, PLoS ONE.

[12]  Sophia Hsin-Jung Li,et al.  Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the Breast , 2011, Cell.

[13]  R. Schiff,et al.  More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response , 2011, Breast Cancer Research.

[14]  Felix Krueger,et al.  Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications , 2011, Bioinform..

[15]  Rachel Schiff,et al.  Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.

[16]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[17]  V. Harley,et al.  Acquisition of SOX transcription factor specificity through protein-protein interaction, modulation of Wnt signalling and post-translational modification. , 2010, The international journal of biochemistry & cell biology.

[18]  Robert L. Sutherland,et al.  Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.

[19]  Huanming Yang,et al.  An improved method for genome wide DNA methylation profiling correlated to transcription and genomic instability in two breast cancer cell lines , 2009, BMC Genomics.

[20]  David J. Nott,et al.  Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup , 2009, PloS one.

[21]  A. Laenkholm,et al.  Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors , 2009, Breast Cancer Research.

[22]  L. Topol,et al.  Sox9 Inhibits Wnt Signaling by Promoting β-Catenin Phosphorylation in the Nucleus* , 2009, Journal of Biological Chemistry.

[23]  M. Dowsett,et al.  ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. , 2008, Endocrine-related cancer.

[24]  Jing Liang,et al.  The Molecular Mechanism Governing the Oncogenic Potential of SOX2 in Breast Cancer* , 2008, Journal of Biological Chemistry.

[25]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[26]  I. Christensen,et al.  Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications , 2008, Acta oncologica.

[27]  B. O’Malley,et al.  Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  I. Weissman,et al.  Pioneer factor interactions and unmethylated CpG dinucleotides mark silent tissue-specific enhancers in embryonic stem cells , 2007, Proceedings of the National Academy of Sciences.

[29]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[30]  D. Santini,et al.  p66Shc/Notch‐3 Interplay Controls Self‐Renewal and Hypoxia Survival in Human Stem/Progenitor Cells of the Mammary Gland Expanded In Vitro as Mammospheres , 2007, Stem cells.

[31]  E. Lander,et al.  The Mammalian Epigenome , 2007, Cell.

[32]  G. Stein,et al.  Establishment of histone gene regulation and cell cycle checkpoint control in human embryonic stem cells , 2007, Journal of cellular physiology.

[33]  Lang Li,et al.  Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. , 2006, Cancer research.

[34]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[35]  O. Nielsen,et al.  Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy , 2006, British Journal of Cancer.

[36]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Lykkesfeldt,et al.  Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. , 2005, Endocrine-related cancer.

[38]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[39]  S. D'souza,et al.  Signalling In The Epidermis: The E2f Cell Cycle Regulatory Pathway In Epidermal Morphogenesis, Regeneration And Transformation , 2005, International journal of biological sciences.

[40]  Mitch Dowsett,et al.  Mechanisms of tamoxifen resistance. , 2004, Endocrine-related cancer.

[41]  I. Weissman,et al.  Therapeutic implications of cancer stem cells. , 2004, Current opinion in genetics & development.

[42]  A. Lykkesfeldt,et al.  Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha. , 2003, Endocrine-related cancer.

[43]  Minetta C. Liu,et al.  Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling , 2003, Oncogene.

[44]  N. Brünner,et al.  Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. , 2003, Endocrine-related cancer.

[45]  G. Dontu,et al.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.

[46]  O. Stål,et al.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.

[47]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[48]  P. Briand,et al.  Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. , 1997, Cancer research.

[49]  J. Foekens,et al.  Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. , 1994, Molecular endocrinology.

[50]  P. Briand,et al.  Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. , 1994, Cancer research.

[51]  R. Clarke,et al.  MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. , 1993, Cancer research.

[52]  R Clarke,et al.  Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. Briand,et al.  Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. , 1986, British Journal of Cancer.

[54]  W. McGuire,et al.  Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[56]  Sébastien Tempel.  Using and understanding RepeatMasker. , 2012, Methods in molecular biology.

[57]  R. Gelber,et al.  Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. , 2008, The Lancet. Oncology.

[58]  P. Lockhart,et al.  Polyalanine expansion mutations in the X-linked hypopituitarism gene SOX3 result in aggresome formation and impaired transactivation. , 2007, Frontiers in bioscience : a journal and virtual library.

[59]  V. Lefebvre,et al.  Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. , 2007, The international journal of biochemistry & cell biology.

[60]  Vincent T. Lombardi,et al.  Acquisition of Hormone-independent Growth in MCF-7 Cells Is Accompanied by Increased Expression of Estrogen-regulated Genes but Without Detectable DNA Amplifications , 2007 .

[61]  Marclippman.  The Effects of Estrogens and Antiestrogens on Hormone responsive Human Breast Cancer in Long-Term Tissue Culture , 2006 .

[62]  R. Schiff,et al.  Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. , 2005, Oncogene.

[63]  P. Briand,et al.  Long-term cultivation of a human breast cancer cell line, MCF-7, in a chemically defined medium. Effect of estradiol. , 1986, Anticancer research.